Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BRII-179 + elebsiran
- Development stage
- Unknown
- Lead developer
- Brii Biosciences
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**BRII-179 + elebsiran** is an investigational combination therapy for chronic hepatitis B virus (HBV) infection. BRII-179 is a novel recombinant protein-based therapeutic vaccine expressing Pre-S1, Pre-S2, and S HBV surface antigens to induce broad B-cell and T-cell immunity, aimed at restoring or enhancing the host immune response against HBV. Elebsiran (previously known as BRII-835) is a small interfering RNA (siRNA)-based therapy designed to selectively silence HBV transcripts, reducing production of hepatitis B surface antigen (HBsAg) and thereby promoting viral clearance. The combination leverages immunostimulation from the vaccine and direct viral suppression by siRNA. This strategy aims to improve functional cure rates for chronic HBV, as indicated by HBsAg loss and seroconversion. The drugs are being developed by Brii Biosciences and are undergoing multi-phase clinical evaluation, including Phase 2 studies assessing immunological and virological endpoints in patients with chronic hepatitis B[1][3][4][5][7][10][11].
- Other names
- VBI-2601VBI2601VBI 2601VIR-2218VIR2218VIR 2218
02
Targets
HBV RNA (Hepatitis B virus RNA)HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on BRII-179 + elebsiran.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BRII-179 + elebsiran.